Abstract:Introduction: A primary impediment to the efficacy of immune checkpoint inhibitors is the lack of biomarkers for therapeutic responses and prognosis. Although patients with clear cell renal cell carcinoma (ccRCC) could be precisely selected for targeted therapy based on somatic mutations, it remains controversial to choose the suitable patients with a high response rate to immune checkpoint inhibitors (ICIs). The immune-dependent roles of tumor suppressor PTEN in the formation of tumor immune microenvironment remain elusive. Methods: We comprehensively analyzed the genomic and transcriptomic data from multiple ccRCC datasets, including bulk-RNA sequencing and single-cell RNA sequencing data. In vitro, immunoblotting, qRT-PCR, and RNA sequencing were conducted in ccRCC cell lines upon PTEN depletion. Gene ontology and gene set enrichment analysis were performed to screen the critical pathway and molecules in response to PTEN deletion. Immunohistochemistry staining and further bioinformatic analysis were used to validate our data. Results: Based on multi-omics analysis of public datasets of renal cancer, the frequently mutated or deleted PTEN was found to be correlated with a suppressive tumor immune microenvironment in ccRCC. Furthermore, we depleted PTEN via CRISPR-Cas9 in Caki-1 cells, which led to the upregulation of multiple neutrophil chemokines, particularly CXCL1, CXCL2, CXCL5, CXCL6, and CXCL8. The roles of neutrophil chemokines and neutrophil markers were further validated and investigated for the association with prognosis in vitro, clinical samples, and the publicly available databases. The expression of CXCL1, CXCL8, and neutrophil markers, S100A9 and BCL2A1, were significantly associated with a poor immunotherapy-related prognosis in public dataset of renal cancer patients receiving ICIs treatment. Conclusion: These results add a new layer to understanding the association between PTEN status and the role of neutrophil infiltration in ccRCC. Moreover, our findings propose low expression of PTEN as candidate factor of resistance to anti-PD-1-based immunotherapy in ccRCC.

Myeloid PTEN Promotes Chemotherapy-Induced NLRP3-inflammasome Activation and Antitumour Immunity

PTENα functions as an immune suppressor and promotes immune resistance in PTEN-mutant cancer

Myeloid PTEN Loss Affects the Therapeutic Response by Promoting Stress Granule Assembly and Impairing Phagocytosis by Macrophages in Breast Cancer

Chemotherapy-induced PTEN-L secretion promotes the selection of PTEN-deficient tumor cells

Secreted PTEN binds PLXDC2 on macrophages to drive antitumor immunity and tumor suppression

The Infiltration of Neutrophil Granulocytes Due to Loss of PTEN Was Associated with Poor Response to Immunotherapy in Renal Cell Carcinoma

Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway

Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer

Genome-wide CRISPR screening identifies critical role of phosphatase and tensin homologous (PTEN) in sensitivity of acute myeloid leukemia to chemotherapy

PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

PTEN Deficiency Facilitates Exosome Secretion and Metastasis in Cholangiocarcinoma by Impairing TFEB-mediated Lysosome Biogenesis

PI3Kβ controls immune evasion in PTEN-deficient breast tumours

The PTEN Pathway in Tregs is a Critical Driver of the Suppressive Tumor Microenvironment

PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma

PTEN-mediated dephosphorylation of 53BP1 confers cellular resistance to DNA damage in cancer cells

Mitotic SENP3 activation couples with cGAS signaling in tumor cells to stimulate anti-tumor immunity

Supplementary Figure S2 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells

MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer

Pten/Pi3k/Mtor/B7-H1 Signaling Pathway Regulates Cell Progression and Immunoresistance in Pancreatic Cancer

Chemotherapy-induced high expression of IL23A enhances efficacy of anti-PD-1 therapy in TNBC by co-activating the PI3K-AKT signaling pathway of CTLs